A gentler chemo schedule may match standard care in advanced pancreatic cancer
A systematic review of five real-world studies finds that a biweekly gemcitabine and nab-paclitaxel schedule matches standard survival outcomes in ...
A systematic review of five real-world studies finds that a biweekly gemcitabine and nab-paclitaxel schedule matches standard survival outcomes in ...
A real-world study of 214 patients finds that adding Bevacizumab to Olaparib maintenance therapy significantly improves overall survival only in ...
A large multinational real-world study found that primary G-CSF prophylaxis reduced severe neutropenia in metastatic triple-negative breast cancer patients treated ...
A six-month multicenter study of 952 Pakistani adults found empagliflozin, alone or with metformin, significantly improved HbA1c, weight, and blood ...
The largest real-world study of its kind shows that quantitative oestrogen and progesterone receptor levels, measured in recent tumour biopsies, ...
A new meta-analysis of five observational studies finds that adding pembrolizumab to neoadjuvant chemotherapy in early-stage triple-negative breast cancer appears ...
A new multicenter observational study called RERUN will evaluate the real-world effectiveness and safety of trastuzumab deruxtecan in about 150 ...
A linked electronic health record and claims analysis of 401 US patients shows most begin abrocitinib at 100 mg, refill ...
A large real-world cohort from Thailand finds that total neoadjuvant therapy doubles pathological complete response rates in locally advanced rectal ...
Interim results from the prospective multicenter MASTRR Registry report no definitively device-related adverse events among 411 patients and 474 complex ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine